Apitegromab improves motor function in spinal muscular atrophy
For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves motor function versus placebo, according to a study published online ...
Aug 25, 2025
0
11









